The Expression of TP63 as a Biomarker of Early Recurrence in Resected Esophageal Squamous Cell Carcinoma after Neoadjuvant Chemoradiotherapy

Author:

Lin Chih-Hung1,Cheng Po-Liang2ORCID,Chuang Cheng-Yeh1,Kang Yu-Ting3ORCID,Lee Li-Wen3,Hsiao Tzu-Hung3456,Hsu Chung-Ping17

Affiliation:

1. Division of Thoracic Surgery, Department of Surgery, Taichung Veterans General Hospital, Taichung 40705, Taiwan

2. Department of Pathology and Laboratory Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA

3. Department of Medical Research, Taichung Veterans General Hospital, Taichung 40705, Taiwan

4. Research Center for Biomedical Science and Engineering, National Tsing Hua University, Hsinchu 30013, Taiwan

5. Department of Public Health, Fu Jen Catholic University, New Taipei City 242062, Taiwan

6. Institute of Genomics and Bioinformatics, National Chung Hsing University, Taichung 40227, Taiwan

7. Division of Thoracic Surgery, Department of Surgery, Buddhist Tzu Chi General Hospital, Hualien 97004, Taiwan

Abstract

Esophageal cancer ranks among the ten most common cancers worldwide. Despite the adoption of neoadjuvant concurrent chemoradiotherapy (nCCRT) followed by surgery as the standard treatment approach in recent years, the local recurrence rate remains high. In this study, we employed RNA-seq to investigate distinctive gene expression profiles in esophageal squamous cell carcinoma (ESCC) with or without recurrence following a standard treatment course. Our findings indicate that recurrent ESCC exhibits heightened keratinizing and epidermis development activity compared to non-recurrent ESCC. We identified TP63 as a potential candidate for distinguishing clinical outcomes. Furthermore, immunohistochemistry confirmed the trend of TP63 overexpression in ESCC recurrence. Patients with elevated TP63 expression had poorer overall survival and lower 3-year recurrence-free survival. This study underscores the potential of TP63 as a biomarker for detecting cancer recurrence and suggests its role in guiding future treatment options.

Funder

National Science and Technology Council, Taiwan

Veterans General Hospital and Taiwan University System (VGHUST) Joint Research Program

Publisher

MDPI AG

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3